Cargando…

Prostate cancer risk prediction using a polygenic risk score

Hereditary factors have a strong influence on prostate cancer (PC) risk and poorer outcomes, thus stratification by genetic factors addresses a critical need for targeted PC screening and risk-adapted follow-up. In this Finnish population-based retrospective study 2283 clinically diagnosed and 455 s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sipeky, Csilla, Talala, Kirsi M., Tammela, Teuvo L. J., Taari, Kimmo, Auvinen, Anssi, Schleutker, Johanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553910/ https://www.ncbi.nlm.nih.gov/pubmed/33051487 http://dx.doi.org/10.1038/s41598-020-74172-z

Ejemplares similares

Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease
por: Sipeky, Csilla, et al.
Publicado: (2021)

Non-Steroidal Anti-Inflammatory Drugs and Cancer Death in the Finnish Prostate Cancer Screening Trial
por: Veitonmäki, Thea, et al.
Publicado: (2016)

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer
por: Murtola, Teemu J., et al.
Publicado: (2018)

Digoxin and prostate cancer survival in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kaapu, Kalle J, et al.
Publicado: (2016)

Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer
por: Kinnunen, Pete T. T., et al.
Publicado: (2017)

Antihypertensive drug use and prostate cancer-specific mortality in Finnish men
por: Siltari, Aino, et al.
Publicado: (2020)

Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer
por: Ola, Idris Olasunmbo, et al.
Publicado: (2022)

Charlson Comorbidity Index Based On Hospital Episode Statistics Performs Adequately In Predicting Mortality, But Its Discriminative Ability Diminishes Over Time
por: Pylväläinen, Juho, et al.
Publicado: (2019)

Long‐term health‐related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer
por: Talala, Kirsi, et al.
Publicado: (2020)

Inverse Association between Statin Use and Cancer Mortality Relates to Cholesterol Level
por: Peltomaa, Antti I., et al.
Publicado: (2022)

Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and Validation
por: Neupane, Subas, et al.
Publicado: (2021)

Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC
por: Pashayan, Nora, et al.
Publicado: (2015)

Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate Cancer
por: Salminen, Jukka K., et al.
Publicado: (2022)

Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men
por: Kaapu, Kalle J., et al.
Publicado: (2018)

Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data
por: Booth, Neill, et al.
Publicado: (2019)

Statin use and outcomes of oncological treatment for castration-resistant prostate cancer
por: Peltomaa, A. I., et al.
Publicado: (2023)

Outcomes of prostate cancer screening among men using antidiabetic medication
por: Vettenranta, A., et al.
Publicado: (2021)

Prostate cancer prognosis after initiation of androgen deprivation therapy among statin users. A population-based cohort study
por: Peltomaa, A. I., et al.
Publicado: (2021)

Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial
por: Veitonmäki, T, et al.
Publicado: (2014)

Population‐based randomized trial of screening for clinically significant prostate cancer ProScreen: a pilot study
por: Rannikko, Antti, et al.
Publicado: (2022)

Assessing Interactions of Two Loci (rs4242382 and rs10486567) in Familial Prostate Cancer: Statistical Evaluation of Epistasis
por: Chen, Li-Sheng, et al.
Publicado: (2014)

Missingness in the expanded prostate cancer index short form (EPIC-26) – prevalence, patterns, and explanatory factors
por: Talvitie, Anna-Maija, et al.
Publicado: (2023)

Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study
por: Hietikko, Ronja, et al.
Publicado: (2020)

MiRNA Profiles in Lymphoblastoid Cell Lines of Finnish Prostate Cancer Families
por: Fischer, Daniel, et al.
Publicado: (2015)

Prostate cancer polygenic risk score and prediction of lethal prostate cancer
por: Klein, Robert J., et al.
Publicado: (2022)

PALB2 variants in hereditary and unselected Finnish Prostate cancer cases
por: Pakkanen, Sanna, et al.
Publicado: (2009)

ANO7 is associated with aggressive prostate cancer
por: Kaikkonen, Elina, et al.
Publicado: (2018)

Contribution of ARLTS1 Cys148Arg (T442C) Variant with Prostate Cancer Risk and ARLTS1 Function in Prostate Cancer Cells
por: Siltanen, Sanna, et al.
Publicado: (2011)

Evaluation of Polygenic Risk Scores for Prediction of Prostate Cancer in Korean Men
por: Oh, Jong Jin, et al.
Publicado: (2020)

Validation of a prostate cancer polygenic risk score
por: Black, Mary H., et al.
Publicado: (2020)

Inherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer
por: Rantapero, Tommi, et al.
Publicado: (2020)

ShAn: An easy-to-use tool for interactive and integrated variant annotation
por: Rathinakannan, Venkat Subramaniam, et al.
Publicado: (2020)

Polygenic risk scores and breast cancer risk prediction
por: Roberts, Eleanor, et al.
Publicado: (2023)

Polygenic Risk Scores for cancer mortality prediction
por: Sciurti, A, et al.
Publicado: (2023)

Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts
por: Seibert, Tyler M, et al.
Publicado: (2018)

NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene
por: Mattila, Henna, et al.
Publicado: (2011)

Polygenic Risk Score Prediction for Endometriosis
por: Kloeve-Mogensen, Kirstine, et al.
Publicado: (2021)

Evaluation of polygenic risk score for risk prediction of gastric cancer
por: Wang, Xiao-Yu, et al.
Publicado: (2023)

The effect of sample size on polygenic hazard models for prostate cancer
por: Karunamuni, Roshan A., et al.
Publicado: (2020)

Early prediction of prostate cancer risk in younger men using polygenic risk scores and electronic health records
por: Varma, Amita, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aep2l8sdc8on1g4lioqkb3vbvk